Collectively, data from these experiments demonstrated that sorafenib-resistant HCC cell lines are chemosensitive to regorafenib, which has been shown to partially exert its anti-cancer actions by targeting the pro-survival FOXO3-induced autophagy. The gene discussed is FOXO3; the disease is hepatocellular carcinoma.